vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at TD Cowen

TD Cowen started coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued to investors on Monday,Benzinga reports. The firm set a “buy” rating and a $67.00 price target on the biotechnology company’s stock. TD Cowen’s price objective would suggest a potential upside of 69.19% from the stock’s previous close.

A number of other equities research analysts have also commented on the stock. HC Wainwright reiterated a “buy” rating and set a $47.00 price target (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Cowen assumed coverage on vTv Therapeutics in a research note on Monday. They issued a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Finally, BTIG Research assumed coverage on vTv Therapeutics in a research note on Wednesday, November 19th. They set a “buy” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $51.33.

vTv Therapeutics Stock Down 1.0%

VTVT opened at $39.60 on Monday. The firm has a 50-day moving average price of $30.51 and a 200-day moving average price of $22.39. vTv Therapeutics has a twelve month low of $13.20 and a twelve month high of $41.49. The company has a market capitalization of $156.02 million, a price-to-earnings ratio of -11.93 and a beta of 0.48.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Institutional Investors Weigh In On vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP boosted its position in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 148,314 shares of the biotechnology company’s stock after purchasing an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned approximately 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.